Drug Patents owned by Astrazeneca Ab

1. List of Breztri Aerosphere drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8703806 ASTRAZENECA AB Compositions, methods and propellant-based systems for respiratory delivery of glycopyrrolate and one or more active agents
May, 2030

(7 years from now)

US9463161 ASTRAZENECA AB Compositions for pulmonary delivery of long-acting muscarinic antagonists and associated methods and systems
May, 2030

(7 years from now)

US9415009 ASTRAZENECA AB Compositions, methods and systems for respiratory delivery of two or more active agents
May, 2030

(7 years from now)

US8324266 ASTRAZENECA AB Compositions, methods and systems for respiratory delivery of two or more active agents
May, 2030

(7 years from now)

US8808713 ASTRAZENECA AB Compositions for pulmonary delivery of long-acting β2 adrenergic receptor agonists and associated methods and systems
May, 2030

(7 years from now)

US10716753 ASTRAZENECA AB Compositions for pulmonary delivery of long-acting muscarinic antagonists or long-acting B2 adrenergic receptor agonists and associated methods and systems
May, 2030

(7 years from now)

US8815258 ASTRAZENECA AB Compositions, methods and systems for respiratory delivery of two or more active agents
Mar, 2031

(8 years from now)

US11331442 ASTRAZENECA AB Drug delivery systems and related methods
May, 2038

(15 years from now)

Exclusivity Exclusivity Expiration
New Combination (NC) Jul 23, 2023

Drugs and Companies using BUDESONIDE; FORMOTEROL FUMARATE; GLYCOPYRROLATE ingredient

Market Authorisation Date: 23 July, 2020

Treatment: Use for the maintenance treatment of patients with chronic obstructive pulmonary disease (copd)

Dosage: AEROSOL, METERED;INHALATION

More Information on Dosage

2. List of Bydureon drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US6515117 ASTRAZENECA AB C-aryl glucoside SGLT2 inhibitors and method
Oct, 2025

(2 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7223440

(Pediatric)

ASTRAZENECA AB Residual solvent extraction method and microparticles produced thereby
Mar, 2022

(11 months ago)

US6824822 ASTRAZENECA AB Residual solvent extraction method and microparticles produced thereby
Oct, 2022

(3 months ago)

US6824822

(Pediatric)

ASTRAZENECA AB Residual solvent extraction method and microparticles produced thereby
Apr, 2023

(2 months from now)

US7563871 ASTRAZENECA AB Polymer-based sustained release device
Apr, 2024

(1 year, 2 months from now)

US9238076 ASTRAZENECA AB Polymer-based sustained release device
Apr, 2024

(1 year, 2 months from now)

US7563871

(Pediatric)

ASTRAZENECA AB Polymer-based sustained release device
Oct, 2024

(1 year, 8 months from now)

US9238076

(Pediatric)

ASTRAZENECA AB Polymer-based sustained release device
Oct, 2024

(1 year, 8 months from now)

US8431685 ASTRAZENECA AB Polymer-based sustained release device
Apr, 2025

(2 years from now)

US7612176 ASTRAZENECA AB Polymer-based sustained release device
Apr, 2025

(2 years from now)

US8461105 ASTRAZENECA AB Polymer-based sustained release device
Apr, 2025

(2 years from now)

US7456254 ASTRAZENECA AB Polymer-based sustained release device
Jun, 2025

(2 years from now)

US8461105

(Pediatric)

ASTRAZENECA AB Polymer-based sustained release device
Oct, 2025

(2 years from now)

US7612176

(Pediatric)

ASTRAZENECA AB Polymer-based sustained release device
Oct, 2025

(2 years from now)

US8431685

(Pediatric)

ASTRAZENECA AB Polymer-based sustained release device
Oct, 2025

(2 years from now)

US7456254

(Pediatric)

ASTRAZENECA AB Polymer-based sustained release device
Dec, 2025

(2 years from now)

US6515117

(Pediatric)

ASTRAZENECA AB C-aryl glucoside SGLT2 inhibitors and method
Apr, 2026

(3 years from now)

US9884092 ASTRAZENECA AB Methods for treating diabetes and reducing body weight
Aug, 2026

(3 years from now)

US8329648 ASTRAZENECA AB Methods for treating diabetes and reducing body weight
Aug, 2026

(3 years from now)

US8906851 ASTRAZENECA AB Method for treating diabetes
Aug, 2026

(3 years from now)

US9884092

(Pediatric)

ASTRAZENECA AB Methods for treating diabetes and reducing body weight
Feb, 2027

(4 years from now)

US8329648

(Pediatric)

ASTRAZENECA AB Methods for treating diabetes and reducing body weight
Feb, 2027

(4 years from now)

US8906851

(Pediatric)

ASTRAZENECA AB Method for treating diabetes
Feb, 2027

(4 years from now)

US8501698 ASTRAZENECA AB Crystal structures of SGLT2 inhibitors and processes for preparing same
Jun, 2027

(4 years from now)

US8758292 ASTRAZENECA AB Administering apparatus with functional drive element
Nov, 2027

(4 years from now)

US8501698

(Pediatric)

ASTRAZENECA AB Crystal structures of SGLT2 inhibitors and processes for preparing same
Dec, 2027

(4 years from now)

US8216180 ASTRAZENECA AB Administering apparatus with functional drive element
Jan, 2028

(4 years from now)

US8361972 ASTRAZENECA AB Pharmaceutical formulations containing an SGLT2 inhibitor
Mar, 2028

(5 years from now)

US9320853 ASTRAZENECA AB Method for administering a fluid active substance from a multi-chamber ampoule
Mar, 2028

(5 years from now)

US8439864 ASTRAZENECA AB Device for administering fluid from a multi-chamber ampoule in incremental steps
Mar, 2028

(5 years from now)

US8758292

(Pediatric)

ASTRAZENECA AB Administering apparatus with functional drive element
May, 2028

(5 years from now)

US8216180

(Pediatric)

ASTRAZENECA AB Administering apparatus with functional drive element
Jul, 2028

(5 years from now)

US8361972

(Pediatric)

ASTRAZENECA AB Pharmaceutical formulations containing an SGLT2 inhibitor
Sep, 2028

(5 years from now)

US9320853

(Pediatric)

ASTRAZENECA AB Method for administering a fluid active substance from a multi-chamber ampoule
Sep, 2028

(5 years from now)

US8439864

(Pediatric)

ASTRAZENECA AB Device for administering fluid from a multi-chamber ampoule in incremental steps
Sep, 2028

(5 years from now)

US8827963 ASTRAZENECA AB Administering device with holding mechanism
Feb, 2029

(6 years from now)

US8690837 ASTRAZENECA AB Mixing device for a two-chamber ampoule
May, 2029

(6 years from now)

US8827963

(Pediatric)

ASTRAZENECA AB Administering device with holding mechanism
Aug, 2029

(6 years from now)

US8690837

(Pediatric)

ASTRAZENECA AB Mixing device for a two-chamber ampoule
Nov, 2029

(6 years from now)

US8998876 ASTRAZENECA AB Ampoule comprising an ampoule holder
Jan, 2030

(6 years from now)

US8721615 ASTRAZENECA AB Ampoule comprising an ampoule holder
Jan, 2030

(6 years from now)

US8998876

(Pediatric)

ASTRAZENECA AB Ampoule comprising an ampoule holder
Jul, 2030

(7 years from now)

US8721615

(Pediatric)

ASTRAZENECA AB Ampoule comprising an ampoule holder
Jul, 2030

(7 years from now)

Exclusivity Exclusivity Expiration
New Patient Population (NPP) Jul 22, 2024
M Feb 15, 2022
Pediatric Exclusivity (PED) Jan 22, 2025

Drugs and Companies using EXENATIDE SYNTHETIC ingredient

Market Authorisation Date: 27 January, 2012

Treatment: As an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus in combination with metformin, a sulfonylurea, a thiazolidinedione, or combination of any two of these therapies; As an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus in combination with basal insulin or basal insulin plus metformin; Improving glycemic control in adults with type 2 diabetes mellitus by administering an exenatide formulation as an adjunct to diet and exercise to provide a release profile having a ratio of c-max to c-avg of about 3 or less; As an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus in combination with dapagliflozin and metformin; As an adjunct to diet and exercise to improve glycemic control in patients 10 to 17 years of age with type 2 diabetes mellitus in combination with metformin and/or sulfonylurea; As an adjunct to diet and exercise to improve glycemic control in patients 10 to 17 years of age with type 2 diabetes mellitus in combination with insulin alone or insulin plus one other oral antidiabetic medication; Improving glycemic control in patients 10 years of age and older with type 2 diabetes mellitus by administering a sustained-release exenatide formulation as an adjunct to diet and exercise; Improving glycemic control in adults with type 2 diabetes mellitus by administering an exenatide formulation once weekly as an adjunct to diet and exercise to achieve a mean steady state plasma concentration of exenatide at least 170 pg/ml; Reducing fasting plasma glucose in adults with type 2 diabetes mellitus by administering an exenatide formulation once weekly as an adjunct to diet and exercise to achieve a mean steady state plasma concentration of exenatide at least 170 pg/ml; Reducing body weight in adults with type 2 diabetes mellitus by administering an exenatide formulation once weekly as an adjunct to diet and exercise to achieve a mean steady state plasma concentration of exenatide at least 170 pg/ml; Reducing hba1c in adults with type 2 diabetes mellitus by administering an exenatide formulation once weekly as an adjunct to diet and exercise to achieve a mean steady state plasma concentration of exenatide at least 170 pg/ml

Dosage: FOR SUSPENSION, EXTENDED RELEASE;SUBCUTANEOUS

More Information on Dosage

3. List of Bydureon Bcise drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US6515117 ASTRAZENECA AB C-aryl glucoside SGLT2 inhibitors and method
Oct, 2025

(2 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7223440

(Pediatric)

ASTRAZENECA AB Residual solvent extraction method and microparticles produced thereby
Mar, 2022

(11 months ago)

US6824822 ASTRAZENECA AB Residual solvent extraction method and microparticles produced thereby
Oct, 2022

(3 months ago)

US6824822

(Pediatric)

ASTRAZENECA AB Residual solvent extraction method and microparticles produced thereby
Apr, 2023

(2 months from now)

US9238076 ASTRAZENECA AB Polymer-based sustained release device
Apr, 2024

(1 year, 2 months from now)

US7563871 ASTRAZENECA AB Polymer-based sustained release device
Apr, 2024

(1 year, 2 months from now)

US9238076

(Pediatric)

ASTRAZENECA AB Polymer-based sustained release device
Oct, 2024

(1 year, 8 months from now)

US7563871

(Pediatric)

ASTRAZENECA AB Polymer-based sustained release device
Oct, 2024

(1 year, 8 months from now)

US8461105 ASTRAZENECA AB Polymer-based sustained release device
Apr, 2025

(2 years from now)

US7612176 ASTRAZENECA AB Polymer-based sustained release device
Apr, 2025

(2 years from now)

US8431685 ASTRAZENECA AB Polymer-based sustained release device
Apr, 2025

(2 years from now)

US7456254 ASTRAZENECA AB Polymer-based sustained release device
Jun, 2025

(2 years from now)

US8461105

(Pediatric)

ASTRAZENECA AB Polymer-based sustained release device
Oct, 2025

(2 years from now)

US7612176

(Pediatric)

ASTRAZENECA AB Polymer-based sustained release device
Oct, 2025

(2 years from now)

US8431685

(Pediatric)

ASTRAZENECA AB Polymer-based sustained release device
Oct, 2025

(2 years from now)

US7456254

(Pediatric)

ASTRAZENECA AB Polymer-based sustained release device
Dec, 2025

(2 years from now)

US6515117

(Pediatric)

ASTRAZENECA AB C-aryl glucoside SGLT2 inhibitors and method
Apr, 2026

(3 years from now)

US8906851 ASTRAZENECA AB Method for treating diabetes
Aug, 2026

(3 years from now)

US9884092 ASTRAZENECA AB Methods for treating diabetes and reducing body weight
Aug, 2026

(3 years from now)

US8329648 ASTRAZENECA AB Methods for treating diabetes and reducing body weight
Aug, 2026

(3 years from now)

US9884092

(Pediatric)

ASTRAZENECA AB Methods for treating diabetes and reducing body weight
Feb, 2027

(4 years from now)

US8329648

(Pediatric)

ASTRAZENECA AB Methods for treating diabetes and reducing body weight
Feb, 2027

(4 years from now)

US8906851

(Pediatric)

ASTRAZENECA AB Method for treating diabetes
Feb, 2027

(4 years from now)

US8501698 ASTRAZENECA AB Crystal structures of SGLT2 inhibitors and processes for preparing same
Jun, 2027

(4 years from now)

US8501698

(Pediatric)

ASTRAZENECA AB Crystal structures of SGLT2 inhibitors and processes for preparing same
Dec, 2027

(4 years from now)

US8361972 ASTRAZENECA AB Pharmaceutical formulations containing an SGLT2 inhibitor
Mar, 2028

(5 years from now)

US8361972

(Pediatric)

ASTRAZENECA AB Pharmaceutical formulations containing an SGLT2 inhibitor
Sep, 2028

(5 years from now)

US8895033 ASTRAZENECA AB Sustained release formulations using non-aqueous carriers
Oct, 2030

(7 years from now)

US8895033

(Pediatric)

ASTRAZENECA AB Sustained release formulations using non-aqueous carriers
Apr, 2031

(8 years from now)

Exclusivity Exclusivity Expiration
New Patient Population (NPP) Jul 22, 2024
M Feb 15, 2022
Pediatric Exclusivity (PED) Jan 22, 2025

Drugs and Companies using EXENATIDE SYNTHETIC ingredient

Market Authorisation Date: 20 October, 2017

Treatment: As an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus in combination with metformin, a sulfonylurea, a thiazolidinedione, or combination of any two of these therapies; Improving glycemic control in adults with type 2 diabetes mellitus by administering an exenatide formulation as an adjunct to diet and exercise to provide a release profile having a ratio of c-max to c-avg of about 3 or less; As an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus in combination with basal insulin or basal insulin plus metformin; As an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus in combination with dapagliflozin as add-on to metformin; As an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus in combination with dapagliflozin and metformin; Improving glycemic control in patients 10 years of age and older with type 2 diabetes mellitus by administering a sustained-release exenatide formulation as an adjunct to diet and exercise; As an adjunct to diet and exercise to improve glycemic control in patients 10 to 17 years of age with type 2 diabetes mellitus in combination with metformin and/or sulfonylurea; As an adjunct to diet and exercise to improve glycemic control in patients 10 to 17 years of age with type 2 diabetes mellitus in combination with insulin alone or insulin plus one other oral antidiabetic medication; Improving glycemic control in adults with type 2 diabetes mellitus by administering an exenatide formulation once weekly as an adjunct to diet and exercise to achieve a mean steady state plasma concentration of exenatide at least 170 pg/ml; Reducing fasting plasma glucose in adults with type 2 diabetes mellitus by administering an exenatide formulation once weekly as an adjunct to diet and exercise to achieve a mean steady state plasma concentration of exenatide at least 170 pg/ml; Reducing hba1c in adults with type 2 diabetes mellitus by administering an exenatide formulation once weekly as an adjunct to diet and exercise to achieve a mean steady state plasma concentration of exenatide at least 170 pg/ml; Reducing body weight in adults with type 2 diabetes mellitus by administering an exenatide formulation once weekly as an adjunct to diet and exercise to achieve a mean steady state plasma concentration of exenatide at least 170 pg/ml; Stimulating insulin release in adults with type 2 diabetes mellitus by administering a pre-mixed exenatide formulation as an adjunct to diet and exercise; Delaying gastric emptying in adults with type 2 diabetes mellitus by administering a pre-mixed exenatide formulation as an adjunct to diet and exercise

Dosage: SUSPENSION, EXTENDED RELEASE;SUBCUTANEOUS

More Information on Dosage

4. List of Farxiga drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US6515117 ASTRAZENECA AB C-aryl glucoside SGLT2 inhibitors and method
Oct, 2025

(2 years from now)

US7919598 ASTRAZENECA AB Crystal structures of SGLT2 inhibitors and processes for preparing same
Dec, 2029

(6 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9238076 ASTRAZENECA AB Polymer-based sustained release device
Apr, 2024

(1 year, 2 months from now)

US8431685 ASTRAZENECA AB Polymer-based sustained release device
Apr, 2025

(2 years from now)

US8461105 ASTRAZENECA AB Polymer-based sustained release device
Apr, 2025

(2 years from now)

US7456254 ASTRAZENECA AB Polymer-based sustained release device
Jun, 2025

(2 years from now)

US8329648 ASTRAZENECA AB Methods for treating diabetes and reducing body weight
Aug, 2026

(3 years from now)

US8906851 ASTRAZENECA AB Method for treating diabetes
Aug, 2026

(3 years from now)

US8501698 ASTRAZENECA AB Crystal structures of SGLT2 inhibitors and processes for preparing same
Jun, 2027

(4 years from now)

US8716251 ASTRAZENECA AB Pharmaceutical formulations containing an SGLT2 inhibitor
Mar, 2028

(5 years from now)

US8221786 ASTRAZENECA AB Pharmaceutical formulations containing an SGLT2 inhibitor
Mar, 2028

(5 years from now)

US8361972 ASTRAZENECA AB Pharmaceutical formulations containing an SGLT2 inhibitor
Mar, 2028

(5 years from now)

US7851502 ASTRAZENECA AB Pharmaceutical formulations containing an SGLT2 inhibitor
Aug, 2028

(5 years from now)

US8721615 ASTRAZENECA AB Ampoule comprising an ampoule holder
Jan, 2030

(6 years from now)

US8685934 ASTRAZENECA AB Methods for treating extreme insulin resistance in patients resistant to previous treatment with other anti-diabetic drugs employing an SGLT2 inhibitor and compositions thereof
May, 2030

(7 years from now)

US10973836 ASTRAZENECA AB Methods of treating heart failure with reduced ejection fraction
Mar, 2040

(17 years from now)

Exclusivity Exclusivity Expiration
M Feb 22, 2022
New Indication (I) Oct 18, 2022

Drugs and Companies using DAPAGLIFLOZIN ingredient

Market Authorisation Date: 08 January, 2014

Treatment: Treatment of type 2 diabetes mellitus in combination with exenatide; Reducing hba1c in a human in need thereof in combination with a sustained-release composition containing exendin-4; Reducing fasting plasma glucose in a human in need thereof in combination with a sustained-release composition containing exendin-4; Treatment of type 2 diabetes mellitus; Treatment of type 2 diabetes mellitus in a patient, wherein glycemic control (hba1c < 7.0%) is not achievable using one or more of insulin, metformin, pioglitazone, or rosiglitazone; Reduction of the risk of cardiovascular death and hospitalization for heart failure in adults with heart failure with reduced ejection fraction and without type ii diabetes

Dosage: TABLET;ORAL

How can I launch a generic of FARXIGA before it's patent expiration?
More Information on Dosage

5. List of Kombiglyze Xr drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
USRE44186 ASTRAZENECA AB Cyclopropyl-fused pyrrolidine-based inhibitors of dipeptidyl peptidase IV and method
Jul, 2023

(5 months from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9339472 ASTRAZENECA AB Coated tablet formulation and method
Jul, 2025

(2 years from now)

US8628799 ASTRAZENECA AB Coated tablet formulation and method
Jul, 2025

(2 years from now)

Drugs and Companies using METFORMIN HYDROCHLORIDE; SAXAGLIPTIN HYDROCHLORIDE ingredient

Market Authorisation Date: 05 November, 2010

Treatment: Method for treating type ii diabetes mellitus by administering saxagliptin in combination with metformin; Adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus when treatment with both saxagliptin and metformin is appropriate

Dosage: TABLET, EXTENDED RELEASE;ORAL

How can I launch a generic of KOMBIGLYZE XR before it's patent expiration?
More Information on Dosage

6. List of Onglyza drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
USRE44186 ASTRAZENECA AB Cyclopropyl-fused pyrrolidine-based inhibitors of dipeptidyl peptidase IV and method
Jul, 2023

(5 months from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7951400 ASTRAZENECA AB Coated tablet formulation and method
Nov, 2028

(5 years from now)

Drugs and Companies using SAXAGLIPTIN HYDROCHLORIDE ingredient

Market Authorisation Date: 31 July, 2009

Treatment: Method for treating type ii diabetes by administering saxagliptin; Method for treating type ii diabetes mellitus by administering saxagliptin alone or in combination with insulin, metformin, a thiazolidinedione, glyburide or metformin plus a sulfonylurea

Dosage: TABLET;ORAL

How can I launch a generic of ONGLYZA before it's patent expiration?
More Information on Dosage

7. List of Qtern drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
USRE44186 ASTRAZENECA AB Cyclopropyl-fused pyrrolidine-based inhibitors of dipeptidyl peptidase IV and method
Jul, 2023

(5 months from now)

US6515117 ASTRAZENECA AB C-aryl glucoside SGLT2 inhibitors and method
Oct, 2025

(2 years from now)

US7919598 ASTRAZENECA AB Crystal structures of SGLT2 inhibitors and processes for preparing same
Dec, 2029

(6 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8628799 ASTRAZENECA AB Coated tablet formulation and method
Jul, 2025

(2 years from now)

US8501698 ASTRAZENECA AB Crystal structures of SGLT2 inhibitors and processes for preparing same
Jun, 2027

(4 years from now)

US8716251 ASTRAZENECA AB Pharmaceutical formulations containing an SGLT2 inhibitor
Mar, 2028

(5 years from now)

US8221786 ASTRAZENECA AB Pharmaceutical formulations containing an SGLT2 inhibitor
Mar, 2028

(5 years from now)

US8361972 ASTRAZENECA AB Pharmaceutical formulations containing an SGLT2 inhibitor
Mar, 2028

(5 years from now)

Exclusivity Exclusivity Expiration
New Strength (NS) May 2, 2022
New Indication (I) May 2, 2022

Drugs and Companies using DAPAGLIFLOZIN; SAXAGLIPTIN HYDROCHLORIDE ingredient

Market Authorisation Date: 27 February, 2017

Treatment: Treatment of type 2 diabetes mellitus; Method for treating type 2 diabetes mellitus (t2dm) in patients who have inadequate control with dapagliflozin; Method for treating type 2 diabetes mellitus (t2dm) in patients who are already treated with dapagliflozin and saxagliptin

Dosage: TABLET;ORAL

How can I launch a generic of QTERN before it's patent expiration?
More Information on Dosage

8. List of Qternmet Xr drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
USRE44186 ASTRAZENECA AB Cyclopropyl-fused pyrrolidine-based inhibitors of dipeptidyl peptidase IV and method
Jul, 2023

(5 months from now)

US6515117 ASTRAZENECA AB C-aryl glucoside SGLT2 inhibitors and method
Oct, 2025

(2 years from now)

US7919598 ASTRAZENECA AB Crystal structures of SGLT2 inhibitors and processes for preparing same
Dec, 2029

(6 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8628799 ASTRAZENECA AB Coated tablet formulation and method
Jul, 2025

(2 years from now)

US8501698 ASTRAZENECA AB Crystal structures of SGLT2 inhibitors and processes for preparing same
Jun, 2027

(4 years from now)

US8716251 ASTRAZENECA AB Pharmaceutical formulations containing an SGLT2 inhibitor
Mar, 2028

(5 years from now)

US9616028 ASTRAZENECA AB Bilayer tablet formulations
Nov, 2030

(7 years from now)

Exclusivity Exclusivity Expiration
New Product (NP) May 2, 2022

Drugs and Companies using DAPAGLIFLOZIN; METFORMIN HYDROCHLORIDE; SAXAGLIPTIN HYDROCHLORIDE ingredient

Market Authorisation Date: 02 May, 2019

Treatment: Treatment of type 2 diabetes mellitus

Dosage: TABLET, EXTENDED RELEASE;ORAL

More Information on Dosage

9. List of Xigduo Xr drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US6515117 ASTRAZENECA AB C-aryl glucoside SGLT2 inhibitors and method
Oct, 2025

(2 years from now)

US7919598 ASTRAZENECA AB Crystal structures of SGLT2 inhibitors and processes for preparing same
Dec, 2029

(6 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8501698 ASTRAZENECA AB Crystal structures of SGLT2 inhibitors and processes for preparing same
Jun, 2027

(4 years from now)

US8685934 ASTRAZENECA AB Methods for treating extreme insulin resistance in patients resistant to previous treatment with other anti-diabetic drugs employing an SGLT2 inhibitor and compositions thereof
May, 2030

(7 years from now)

US9616028 ASTRAZENECA AB Bilayer tablet formulations
Nov, 2030

(7 years from now)

Exclusivity Exclusivity Expiration
New Indication (I) Oct 18, 2022
M Feb 22, 2022

Drugs and Companies using DAPAGLIFLOZIN; METFORMIN HYDROCHLORIDE ingredient

Market Authorisation Date: 29 October, 2014

Treatment: Treatment of type 2 diabetes mellitus; Treatment of type 2 diabetes mellitus in a patient, wherein glycemic control (hba1c < 7.0%) is not achievable using one or more of insulin, metformin, pioglitazone, or rosiglitazone

Dosage: TABLET, EXTENDED RELEASE;ORAL

How can I launch a generic of XIGDUO XR before it's patent expiration?
More Information on Dosage

availability in other generic markets.

Click on the highlighted region to filter.

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic

Other things you might be interested in